Novo Nordisk A/S (NYSE:NVO) Given Average Recommendation of “Hold” by Brokerages

Shares of Novo Nordisk A/S (NYSE:NVO) have been assigned a consensus rating of “Hold” from the twenty-one ratings firms that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, fourteen have given a hold recommendation and five have issued a buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $65.5625.

A number of research firms recently weighed in on NVO. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, June 20th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Finally, Citigroup reissued a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, July 20th.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk beat second-quarter expectations, with adjusted sales rising 7% at constant exchange rates and adjusted operating profit increasing 11%. The company also raised its full-year sales and operating-profit outlook, citing continued demand for Wegovy and Ozempic, higher-dose injections and broader GLP-1 volume growth. Novo Nordisk’s Q2 profit beats forecasts, raises outlook
• Positive Sentiment: A Dutch court granted Novo a preliminary injunction against Ceban over an unapproved compounded semaglutide nasal spray, ordering the company to stop infringing activity and remove product listings. The ruling could help protect Novo’s semaglutide intellectual property and branded-product demand. Novo Nordisk wins Dutch court injunction
• Neutral Sentiment: CEO Mike Doustdar said Novo will prioritize faster internal research and smaller “bolt-on” acquisitions rather than transformational mergers. The strategy may conserve capital, but it also leaves investors looking for stronger pipeline evidence. Novo Nordisk not currently in a position to pursue large-scale M&A
• Negative Sentiment: Sales of the oral Wegovy pill were weaker than investors expected, raising concerns about the product’s launch trajectory and pricing economics. Analysts also noted that some quarterly strength came from rebate adjustments and other potentially temporary factors. Novo Nordisk’s raised forecast fails to change the debate over its obesity business
• Negative Sentiment: A setback in the late-stage CagriSema obesity-and-diabetes program weakened confidence in Novo’s next-generation pipeline. Investors are concerned that future products may not be sufficient to offset patent expirations, price reductions and intensifying competition from Lilly. Lilly climbs, Novo falls as obesity drug battle intensifies
• Negative Sentiment: Eli Lilly’s competing GLP-1 franchise delivered a 48% revenue increase to nearly $23 billion, substantially exceeding estimates. The result intensified concerns that Lilly is widening its commercial lead and capturing more of the fast-growing weight-loss market. Eli Lilly stock jumps as GLP-1 sales widen Novo lead

Novo Nordisk A/S Stock Performance

NVO stock opened at $44.48 on Thursday. Novo Nordisk A/S has a twelve month low of $35.12 and a twelve month high of $64.16. The business’s fifty day simple moving average is $46.96 and its two-hundred day simple moving average is $45.12. The firm has a market cap of $198.60 billion, a price-to-earnings ratio of 10.88, a PEG ratio of 4.03 and a beta of 0.76. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The company had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. Analysts predict that Novo Nordisk A/S will post 3.39 earnings per share for the current year.

Institutional Investors Weigh In On Novo Nordisk A/S

Several hedge funds have recently bought and sold shares of the stock. Platform Technology Partners boosted its holdings in Novo Nordisk A/S by 39.2% during the second quarter. Platform Technology Partners now owns 10,941 shares of the company’s stock worth $525,000 after buying an additional 3,079 shares in the last quarter. Fortis Group Advisors LLC lifted its position in shares of Novo Nordisk A/S by 145.5% during the 2nd quarter. Fortis Group Advisors LLC now owns 72,916 shares of the company’s stock valued at $3,496,000 after buying an additional 43,213 shares in the last quarter. Allen Wealth Management LLC acquired a new stake in Novo Nordisk A/S in the 2nd quarter valued at $205,000. Pine Valley Investments Ltd Liability Co acquired a new stake in Novo Nordisk A/S in the 2nd quarter valued at $2,324,000. Finally, Avidian Wealth Enterprises LLC increased its holdings in Novo Nordisk A/S by 17.5% in the 2nd quarter. Avidian Wealth Enterprises LLC now owns 31,634 shares of the company’s stock worth $1,517,000 after acquiring an additional 4,708 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.